Medine.co.uk

Hylartil Vet 10 Mg/Ml Solution For Injection

Revised: April 2014

AN: 01715/2013


SUMMARY OF PRODUCT CHARACTERISTICS


NAME OF THE VETERINARY MEDICINAL PRODUCT


HYLARTIL VET 10 mg/ml Solution for Injection


QUALITATIVE AND QUANTITATIVE COMPOSITION


Each 2ml syringe contains:


Active substance:

Sodium Hyaluronate

(MrM, mean relative molecular mass ≥ 3.0 x106) 20.00 mg (10mg/ml)


For full list of excipients, see Section 6.1.


PHARMACEUTICAL FORM


Solution for injection.


CLINICAL PARTICULARS


Target species


Horses.


Indications for use, specifying the target species


Hylartil Vet (10mg/ml) is indicated for use in horses as follows:


For the local treatment of non-infectious inflammatory joint disease in horses.


For the local treatment of tendinitis in horses.


Contraindications


None.


Special warnings for each target species


None known.


Special precautions for use


Please note the syringe is sealed with a membrane which must be ruptured prior to use (see directions in carton).


Special precautions for use in animals


None known.


Special precautions to be taken by the person administering the veterinary medicinal product to animals


Directly after use of this product, hands and exposed skin should be washed thoroughly.


Adverse reactions (frequency and seriousness)


Transient swelling may occur at the injection site.


Use during pregnancy, lactation or lay


Hylartil Vet can, as far is known, be used during pregnancy and lactation.


Interaction with other medicinal products and other forms of interaction


None known.


Amounts to be administered and administration route


For intra-articular use and direct injection into tendons.


Two ml (20 mg) of Hylartil Vet is given intra-articularly in small and medium size joints and can also be injected directly into tendons. In the treatment of larger joints/tendons the dosage may be increased to 4 ml (40 mg). The injection should be given under strict aseptic conditions. The treatment may be repeated at weekly intervals for a total of three treatments. Not more than two joints/tendons should be treated at the same time.


When performing intra-articular injections care should be taken not to scratch the cartilage surface, as this may result in diffuse swelling lasting for 24 to 48 hours. The transient swelling will have no effect on the ultimate clinical result. For best results the horse should be given a two day stall rest before gradually resuming normal activity.


The syringe must only be used once.


Overdose (symptoms, emergency procedures, antidotes), if necessary


None known.


Withdrawal period


Do not use in horses intended for human consumption.

Treated horses may never be used for human consumption.

The horse must have been declared as not intended for human consumption under national horse passport legislation.


PHARMACOLOGICAL PROPERTIES


Hylartil Vet contains sodium hyaluronate. Sodium hyaluronate is a polysaccharide consisting of repeating units of N-acetylglucosamine and sodium glucuronate linked by glycosidic bonds. It is a natural substance, occurring in identical forms in all species.


ATCVet code:QM09AX01


PHARMACEUTICAL PARTICULARS


List of excipients


Sodium Chloride

Sodium Phosphate Dihydrate

Sodium Acid Phosphate Dihydrate

Sodium hydroxide (pH adjustment)

Hydrochloric acid (pH adjustment)

Water for Injections


Incompatibilities


In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.


Shelf life


Shelf life of the veterinary medicinal product as packaged for sale: 3 years.


Special precautions for storage


Store in a refrigerator (2°C to 8°C). Do not freeze. Protect from light.


The product does not contain an antimicrobial preservative. Any product remaining in the syringe following administration of the required dose should be discarded.


Nature and composition of immediate packaging


A disposable single use 2ml prefilled parenteral syringe of colourless Type I glass, closed with a blue chlorobutyl rubber stopper. Supplied in cartons containing 1 or 20 syringes.

Not all pack sizes may be marketed.


Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products, if appropriate


Any unused product or waste material should be disposed of in accordance with national requirements.


MARKETING AUTHORISATION HOLDER


Zoetis UK Limited

5th Floor, 6 St. Andrew Street

London

EC4A 3AE


MARKETING AUTHORISATION NUMBER


Vm:42058/4071


RENEWAL OF THE AUTHORISATION


Date:6 March 2006


DATE OF REVISION OF THE TEXT


Date:April 2014



Approved: 30/04/2014

Page 4 of 4